Synapse - Michael Mauro

Results (276)

The impact of ponatinib versus allogeneic stem cell transplant (SCT) on outcomes in patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL) with the T315I mutation

Meeting Abstract

Nicolini, F. E.; Basak, G. W.; Kim, D. W.; Olavarria, E.; Pinilla-Ibarz, J.; Apperley, J. F.; Hughes, T. P.; Niederwieser, D.; Mauro, M. J.; Chuah, C.; more...
Blood (2015)

Fulltext@MSK | Save

ABL001, a potent, allosteric inhibitor of BCR-ABL, exhibits safety and promising single- agent activity in a phase I study of patients with CML with failure of prior TKI therapy

Meeting Abstract

Ottmann, O. G.; Alimena, G.; DeAngelo, D. J.; Goh, Y. T.; Heinrich, M. C.; Hochhaus, A.; Hughes, T. P.; Mahon, F. X.; Mauro, M. J.; Minami, H.; more...
Blood (2015)

Fulltext@MSK | Save

Real-world ponatinib prescribing patterns and outcomes in US patients

Meeting Abstract

Mauro, M. J.; McGarry, L. J.; Yang, M.; Lustgarten, S.; Huang, H.
Blood (2015)

Fulltext@MSK | Save

Elevated blood pressure (BP) and adverse events of hypertension (HTN) in phase 1, 2, and 3 trials of ponatinib in leukemia

Meeting Abstract

Guilhot, F.; Khoury, H. J.; Baccarani, M.; Hochhaus, A.; Hughes, T. P.; Lipton, J. H.; Lustgarten, S.; Yanase, K.; Conlan, M. G.; Cortes, J. E.; more...
Haematologica (2015)

Fulltext@MSK | Save

Cardiovascular (CV)-related hospitalization in patients with chronic-phase chronic myeloid leukemia (CP-CML) in SIMPLICITY, a prospective observational study

Meeting Abstract

Paquette, R.; Mauro, M.; Simonsson, B.; Abruzzese, E.; Andorksy, D.; Hansen, R.; Subar, M.; Turner, M.; Zyczynski, T.; Mohamed, H.; more...
Haematologica (2015)

Fulltext@MSK | Save

Cardiovascular (CV) and pulmonary adverse events (AES) in patients (PTS) treated with BCR-ABL tyrosine kinase inhibitors (TKIS): Updated analysis from the FDA Adverse Event Reporting System (FAERS)